RAPT — Rapt Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $123.03m
- -$56.25m
- 37
- 43
- 50
- 39
Annual cashflow statement for Rapt Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.9 | -69.2 | -83.8 | -117 | -130 |
| Depreciation | |||||
| Non-Cash Items | 8.93 | 11.5 | 13.4 | 13 | 19.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.34 | -4.3 | -1.33 | 5.5 | 25.9 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -40.5 | -61 | -70.8 | -97 | -83.3 |
| Capital Expenditures | -0.398 | -0.755 | -0.845 | -1.13 | -0.122 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -87 | -80.6 | -44.6 | 105 | 52.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -87.4 | -81.3 | -45.5 | 104 | 52.7 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 75.5 | 141 | 131 | 1.45 | 153 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -52.5 | -0.891 | 14.9 | 8.53 | 122 |